Entera Bio

Entera Bio Change in Working Capital

The Change in Working Capital of Entera Bio (ENTX) as of Nov 22, 2026 is 1.26 M USD. In the previous year, Change in Working Capital was 112,000.00 USD — a change of 1,022.32% (higher).

Change in Working Capital

1.26 MUSD

YoY

1,022.32%

Last updated:

Change in Working Capital of Entera Bio is 2025 1.26 M USD. Change in Working Capital of Entera Bio was 2024 112,000.00 USD. It decreases by 1,022.32% higher compared to the previous year.

The Entera Bio Change in Working Capital history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Change in Working Capital
Date
Change in Working Capital
Jan 1, 2018
-506,000.00 USD
Jan 1, 2019
691,000.00 USD
Jan 1, 2020
-351,000.00 USD
Jan 1, 2021
1.41 M USD
Jan 1, 2022
-1.84 M USD
Jan 1, 2023
-195,000.00 USD
Jan 1, 2024
112,000.00 USD
Jan 1, 2025
1.26 M USD
The Entera Bio Change in Working Capital history
YEARChange in Working CapitalYoY
1.26 MUSD+1,022.32%
112,000.00USD-157.44%
-195,000.00USD-89.37%
-1.84 MUSD-230.23%
1.41 MUSD-501.42%
-351,000.00USD-150.80%
691,000.00USD-236.56%
-506,000.00USD-155.67%
909,000.00USD+157.51%
353,000.00USD-292.90%
-183,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entera Bio Stock analysis

What does Entera Bio do? Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide. Entera Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entera Bio stock

Change in Working Capital of Entera Bio is 1.26 M USD in 2025.

Change in Working Capital of Entera Bio changed from 112,000.00 USD to 1.26 M USD, representing a 1,022.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Change in Working Capital Entera Bio since 2006 – with annual values, charts, and detailed analysis.

Change in working capital reflects the period-over-period change in current assets minus current liabilities. It impacts operating cash flow significantly.

Change in Working Capital's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Change in Working Capital's Entera Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Entera Bio

All Key Metrics — Entera Bio